[Angioimmunoblastic T-cell lymphoma as a very poor-prognosis malignancy--a single centre experience].
BACKGROUND
Angioimmunoblastic T-lymphoma (AITL) is a poor prognosis malignancy. Because of relatively rare incidence and lack of publications in Czech, we decided to share our experience.


METHODS
Retrospective analysis of newly diagnosed AITL patients treated at our institution between 1/2000-12/2010.


RESULTS
Twelve patients with median age of 64 (43-82) years were analysed. Two patients over 80 years were treated with corticosteroids. Ten patients were treated with 6 cycles of CHOP-21 chemotherapy resulting in: 2/10 (20%) stable disease, 5/10 (50%) partial remission and 3/10 (30%) complete remission. The median EFS and OS of chemotherapy-treated patients were 8 and 10 months, resp. The EFS and OS were both significantly longer in patients who achieved complete remission within the first line of CHOP or autologous stem cells transplantation therapy: 43 vs 6 (p = 0.0052) and 46 vs 6 months (p = 0.0023), respectively. It was not possible to perform autologous transplantation in 4/7 (57%) patients in need for further reduction of the disease because of poor performance status or early progression of lymphoma and death during salvage chemotherapy.


CONCLUSIONS
AITL is a poor prognosis malignancy with a very high risk of early relapse after CHOP induction chemotherapy. In fit patients, autologous transplantation should be performed immediately after induction chemotherapy; information about availability of stem cells donor, both in the family or any available register, should be found during the induction treatment.
Hematologicko-onkologické oddělení, FN Plzeň. vokurka@fnplzen.cz
S
S
Vokurka
V
V
Koza
V
V
Vozobulová
P
P
Jindra
K
K
Steinerová
M
M
Schützová
L
L
Boudová
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D006801:Humans; D007119:Immunoblastic Lymphadenopathy / Q000473:pathology / Q000628:therapy*; D016399:Lymphoma, T-Cell / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011379:Prognosis